Combinations of mesna with cyclophosphamide or adriamycin in the treatment of mice with tumors

• Published in: Cancer research (Chicago, Ill.) Ill.), 1987-02, Vol.47 (3), p.799-802
• Main Authors: BERNACKI, R. J, BANSAL, S. K, GURTOO, H. L
• Format: Article
• Language: English
• Subjects: Animals; Antineoplastic agents; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - toxicity; Biological and medical sciences; Chemotherapy; Colonic Neoplasms - drug therapy; Cyclophosphamide - administration & dosage; Cyclophosphamide - therapeutic use; Doxorubicin - administration & dosage; Doxorubicin - therapeutic use; Female; Leukemia, Experimental - drug therapy; Lung Neoplasms - drug therapy; Medical sciences; Melanoma, Experimental - drug therapy; Mercaptoethanol - analogs & derivatives; Mesna - administration & dosage; Mesna - therapeutic use; Mice; Mice, Inbred Strains; Neoplasms, Experimental - drug therapy; Pharmacology. Drug treatments; Sarcoma, Experimental - drug therapy
• ISSN: 0008-5472; 1538-7445

Following therapeutic administration, cyclophosphamide and Adriamycin are biotransformed to reactive metabolites, some of which are responsible for undesirable systemic toxicities of these chemicals, whereas others are responsible for their chemotherapeutic effectiveness. Microsomal mixed function oxidases activate cyclophosphamide to produce phosphoramide mustard and acrolein, while cytochrome reductase and xanthine oxidase are capable of transforming Adriamycin and forming free radicals. These reactive metabolites produce unwanted toxic side effects; however, their action may be partially ameliorated by the concomitant administration of thiols. In this study we evaluated the therapeutic activity of combinations of mesna (2-mercaptoethanesulfonate) with cyclophosphamide or Adriamycin in mice with a variety of transplantable tumors (L1210 and P-388 leukemia, Lewis lung and colon 26 carcinoma, B16 melanoma, and M5076 sarcoma). In all cases the administration of mesna prior to cyclophosphamide or Adriamycin treatment did not reduce the antitumor effectiveness of these agents and in some instances (C57BL/6 mice with B16 melanoma or M5076 sarcoma) small improvements were observed. Therefore, the addition of thiols, to reduce effectively the buildup of toxic metabolites of cyclophosphamide or Adriamycin may result in the improved therapeutic effectiveness for these agents in the treatment of cancer.